Study of Vosaroxin With Azacitidine in Patients With Newly Diagnosed Acute Myeloid Leukemia or Myelodysplastic Syndrome With Excess Blasts-2
- Status
- COMPLETED
- Phase
- PHASE2
Clinical Trials Related to Azacitidine
Related studies linked through entity extraction aliases.
Selumetinib and Azacitidine in High Risk Chronic Blood Cancers
- Status
- RECRUITING
- Phase
- PHASE1
A Study of DCLL9718S in Participants With Relapsed or Refractory Acute Myeloid Leukemia (AML) or DCLL9718S in Combination With Azacitidine in Participants With Previously Untreated AML Unsuitable for Intensive Induction Chemotherapy
- Status
- COMPLETED
- Phase
- PHASE1
Prognostic Factors and the Impact of Various Management of Acute Myeloid Leukemia in Real Life Condition
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- N/A
Pevonedistat Plus Azacitidine Versus Single-Agent Azacitidine as First-Line Treatment for Participants With Higher-Risk Myelodysplastic Syndromes (HR MDS), Chronic Myelomonocytic Leukemia (CMML), or Low-Blast Acute Myelogenous Leukemia (AML)
- Status
- COMPLETED
- Phase
- PHASE3
Azacitidine and Pembrolizumab in Pancreatic Cancer
- Status
- COMPLETED
- Phase
- PHASE2
Nivolumab With Chemotherapy in Refractory MDS
- Status
- TERMINATED
- Phase
- PHASE1/PHASE2
Magrolimab Monotherapy or Magrolimab in Combination With Azacitidine in Participants With Hematological Malignancies
- Status
- TERMINATED
- Phase
- PHASE1
Geriatric Assessment & Genetic Profiling to Personalize Therapy in Older Adults With Acute Myeloid Leukemia
- Status
- COMPLETED
- Phase
- PHASE2
Safety, Tolerability, Pharmacokinetics, and Efficacy of AZD2811 Nanoparticles as Monotherapy or in Combination in Acute Myeloid Leukemia Participants.
- Status
- TERMINATED
- Phase
- PHASE1
Study of Venetoclax in Combination With Chemotherapy in Pediatric Patients With Refractory or Relapsed Acute Myeloid Leukemia or Acute Leukemia of Ambiguous Lineage
- Status
- COMPLETED
- Phase
- PHASE1
Study of AG-120 (Ivosidenib) vs. Placebo in Combination With Azacitidine in Participants With Previously Untreated Acute Myeloid Leukemia With an IDH1 Mutation
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE3
A Trial of Epigenetic Priming in Patients With Newly Diagnosed Acute Myeloid Leukemia
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
An Efficacy and Safety Study Of Pracinostat In Combination With Azacitidine In Adults With Acute Myeloid Leukemia
- Status
- TERMINATED
- Phase
- PHASE3
A Safety and Efficacy Study of Pracinostat and Azacitidine in Patients With High Risk Myelodysplastic Syndromes
- Status
- TERMINATED
- Phase
- PHASE2
Recombinant EphB4-HSA Fusion Protein and Azacitidine or Decitabine for Relapsed or Refractory Myelodysplastic Syndrome, Chronic Myelomonocytic Leukemia, or Acute Myeloid Leukemia Patients Previously Treated With a Hypomethylating Agent
- Status
- TERMINATED
- Phase
- PHASE2
SL-401 in Combination With Azacitidine or Azacitidine/Venetoclax in Acute Myeloid Leukemia (AML), High-Risk Myelodysplastic Syndrome (MDS) or Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)
- Status
- RECRUITING
- Phase
- PHASE1
Azacitidine and Pembrolizumab in Treating Patients With Myelodysplastic Syndrome
- Status
- UNKNOWN
- Phase
- PHASE2
Azacitidine With or Without Nivolumab or Midostaurin, or Decitabine and Cytarabine Alone in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome
- Status
- COMPLETED
- Phase
- PHASE2/PHASE3
Phase 1b/2 Safety and Efficacy of APR-246 w/Azacitidine for tx of TP53 Mutant Myeloid Neoplasms
- Status
- COMPLETED
- Phase
- PHASE1/PHASE2